Menopause after breast cancer: a survey on breast cancer survivors

Due to the younger age and the ever wider use of adjuvant chemotherapy and antiestrogens, menopausal symptoms are a frequent cause of concern for breast cancer patients. Objectives: To determine the prevalence of menopausal symptoms, and to explore the attitudes toward Hormone Replacement Therapy (HRT) or other treatments and the willingness to take oestrogen in breast cancer patients. Methods: A questionnaire-based survey on 250 breast cancer patients treated and followed-up at our department. Of them 144 (Group A) were in postmenopause and 106 (Group B) were in premenopause at time of diagnosis. Results: Adjuvant therapy with tamoxifen or tamoxifen plus chemotherapy is associated with a significant worsening of menopause-related symptoms of women belonging to Group A. These women are more concerned about risk of breast cancer recurrence than about risk of osteoporosis (P = 0.05) and heart disease (P = 0.006). Seventy-eight percent are against the use of HRT; only 22% would consider taking HRT mainly for vasomotor symptoms relief and osteoporosis prevention. The incidence of vasomotor and dystrophic symptoms is significantly higher in women belonging to Group B treated with chemotherapy and/or hormonotherapy as compared with postmenopausal women (P < 0.000 and P = 0.02, respectively). Premenopausal women are more concerned about risk of breast cancer recurrence than older women (P = 0.09) and at the same time are significantly more worried about the impairment of the quality of life due to adjuvant therapy (P = 0.005). Younger women are more prone to consider HRT than postmenopausal women (P = 0.05). Sixty-six percent are against HRT use, and 34% would consider taking. HRT to alleviate vasomotor and dystrophic symptoms and to prevent osteoporosis. Conclusions: Breast cancer survivors are interested to treatments that may improve their quality of life, but fear of HRT persists among these women and their doctors, despite new evidence suggesting the low probability of detrimental effects. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.